Agilent Settles Key Intellectual Property Case in China EChrom and Pannatek Admit to using Agilent Technology Without Permission, Agree to Pay Damages and Cease Using Agilent Technology SANTA CLARA, Calif., July 31, 2019 Agilent Technologies, Inc. (NYSE: A) today announced that the company has reached agreement with China-based companies EChrom and Pannatek, as well as... Read more
Agilent Companion Diagnostic Gains Expanded FDA Approval in Esophageal Squamous Cell Carcinoma (ESCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify ESCC patients SANTA CLARA, Calif., July 31, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC... Read more
Agilent to Acquire BioTek, Strengthening Leadership Position in Growing Cell Analysis Segment SANTA CLARA, Calif., July 11, 2019 Highlights: Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis BioTek is a recognized leader for plate-readers and imaging systems with complementary... Read more
Agilent Introduces Breakthrough Flow Cytometer SANTA CLARA, Calif., June 24, 2019 Agilent Technologies Inc. (NYSE: A) today introduced its first new product from recently acquired ACEA Biosciences, at the 34th Congress of the International Society for Advancement of Cytometry, CYTO 2019 Congress, being held June 22–26, 2019 in Vancouver, Canada. The Agilent NovoCyte Advanteon Flow... Read more
June 18, 2019 BioTek is pleased to announce that its Synergy™ H1 and Synergy Neo2 Hybrid Multi-Mode Readers and its Cytation™ 1 and Cytation 5 Cell Imaging Multi-Mode Readers are validated for use with the MitoXpress and pH-Xtra Assays from Agilent Technologies. The assays may be used alone or combined to measure metabolism in live cells. Instructional Applications Bulletins are available for each multi-mode reader detailing the specific parameters... Read more
New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases SANTA CLARA, Calif., June 18, 2019 Agilent Technologies Inc. (NYSE: A) today announced the opening of a production facility in Colorado that more than doubles its capacity to develop and manufacture “oligos,” which are short DNA and... Read more
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., June 11, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration... Read more
Agilent Technologies Announces Webcasts for Investment Community SANTA CLARA, Calif., June 4, 2019 Agilent Technologies Inc. (NYSE: A) today announced the following upcoming webcasts for the investment community: Jefferies 2019 Healthcare Conference Thursday, June 6, at 11:00 a.m. (ET)Grand Hyatt, New YorkBob McMahon, Agilent chief financial officer Goldman Sachs 40th Annual Global Healthcare ConferenceTuesday, June... Read more
Agilent Survey of Pharma Lab Leaders Uncovers Challenges in Workflow and Laboratory Efficiencies SANTA CLARA, Calif., June 4, 2019 Agilent Technologies Inc. (NYSE: A) announced today the results of its first Pharma Lab Leaders Survey looking to gather insights from pharmaceutical, biopharmaceutical, and contract research laboratories in seven countries around the world. Respondents included 650... Read more
Agilent Introduces Intelligent LC/MS System for Chromatographers at ASMS 2019 An intuitive quadrupole that incorporates ‘designed-in’ smart features SANTA CLARA, Calif., June 3, 2019 Agilent Technologies Inc. (NYSE: A) ) introduced the newest member of its LC/MS portfolio today at the American Society for Mass Spectrometry Conference (ASMS) which is being held June 2 through... Read more